Crossmark

rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors

Crossref DOI link: https://doi.org/10.1136/jitc-2023-008001

Published Online: 2024-03-12

Published Print: 2024-03

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Lee, Minji https://orcid.org/0000-0003-2957-4457
Im, Sun-Kyoung

Baek, Seungtae

Ji, Mankyu

Kim, Miyoung

Lee, Eun Ju

Ji, Seung Taek

Ferrando-Martinez, Sara

Wolfarth, Alexandra

Lee, Jun-Young

Kim, Daeun

Choi, Donghoon
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05525247 at ClinicalTrials.gov

Documents that mention this clinical trial

rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors
https://doi.org/10.1136/jitc-2023-008001
License Information

License valid from 2024-03-11

Document is current

Any future updates will be listed below